Thymalin
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Thymalin is the founding member of the Khavinson short-peptide bioregulator family — a body of research that began in 1970s Soviet military medicine at the Military Medical Academy in Leningrad, where researchers extracted tissue-specific peptide fractions from animal organs and observed bioactive effects when re-administered, especially in aged tissue. Vladimir Khavinson became the program’s central figure, and after 1991 the St. Petersburg Institute of Bioregulation and Gerontology became its institutional home.
Thymalin itself is the first-generation, extract-based product of that program: a polypeptide complex extracted from thymus tissue, not a synthesized single sequence like its “descendants” Thymagen and Vilon. Profiled by thepeptidelist.com under anti-aging (secondary use: immune), with an evidence tier of Moderate — 30 studies cited, 19 of them human. Thymalin is also one of the few Khavinson-family peptides with an actual clinical-use approval in Russia, alongside the related cortex peptide Cortexin.
What does it do in my body?
Claimed mechanism: thymus-derived peptides supporting T-cell development and immune-system function — restoring immune competence in the aging (involuting) thymus, the organ where T-cells mature.
This sits inside the broader Khavinson-family theoretical claim: that short tissue-derived peptides can cross cell and nuclear membranes, bind DNA promoter regions, and modulate transcription in a tissue-specific way — with Thymalin’s extract acting as a “regulatory signal” for the thymus. In-vitro work across the family supports the underlying nuclear-penetration mechanism: short Khavinson peptides have been shown to penetrate HeLa-cell nuclei and interact with DNA (Fedoreyeva et al. 2011, Biochemistry (Mosc), 22117547), and to drive heterochromatin decondensation and gene reactivation in lymphocytes from elderly subjects (Khavinson, Lezhava, Malinin 2004, Bull Exp Biol Med, 15085253).
How can it help me?
- Where the science stands: Deepest human record in the Khavinson family — 30 studies cited, 19 human — but zero RCTs; all Russian cohort work
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
The reported adverse-event profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle. No serious AEs documented at standard doses.
The real risk with Thymalin isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space. Most buyers are sourcing a Russian-school peptide from a forum link with no way to verify identity or purity, and counterfeit/mislabeled product is the most common failure mode for exactly these compounds — Thymalin included, and arguably more so given it’s a tissue-extract mixture rather than a single synthesizable sequence, which makes it harder to verify by casual means. Third-party COA verification matters more here than for almost any other peptide class.
Regulatory status: Thymalin is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance. Notably, Thymalin and the related cortex peptide Cortexin hold clinical-use approvals in Russia — that approval does not extend to the US.
Part 1 — How to reconstitute it
What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.
The exact bacteriostatic-water volume and resulting concentration for Thymalin are covered in the dosing notes and the deeper-science view. Confirm the right volume for your vial before mixing.
How to mix it
- Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
- Swirl gently to dissolve. Never shake — shaking can damage the peptide.
- Store the reconstituted vial refrigerated and out of light.
- Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.
Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.
Part 2 — Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.
Educational purposes only — this reflects what Russian-school protocols and the peptide community actually use, stated plainly; it is not medical advice.
There is no Western-validated dosing protocol for Thymalin. What exists is the Khavinson-school cycle pattern shared across the whole family (see the Khavinson bioregulator family and Epithalon for the same cycle logic):
- Cycle structure: a short course — typically 10–20 consecutive days — followed by a long rest, repeated 2–3 times per year. The framework claims effects persist 2–3 months past the end of a cycle (an “epigenetic-like persistence” rationale for cycling instead of continuous dosing) — asserted by the Khavinson program, not independently confirmed.
- Thymalin specifically: historically given as a small intramuscular injection over a short in-clinic course in Russian protocols exact mg — because it’s a tissue extract rather than a single synthetic sequence, its dosing convention differs from the synthetic short peptides in the family (which run ~100–200 mcg/day).
- Storage: lyophilized powder is stable cold; once reconstituted with bacteriostatic water, refrigerate and use within roughly 28 days.
Because per-peptide human dose-finding data doesn’t exist for this family, treat every number above as community/Russian-protocol convergence, not a validated dose.
Turning milligrams into syringe units. On a U-100 syringe, 100 units = 1 mL, so 1 unit = 0.01 mL. At a concentration of C mg/mL, a dose of D mg = D ÷ C mL = (D ÷ C) × 100 units. Example: at 5 mg/mL, a 0.5 mg dose = 0.1 mL = 10 units. Your exact units depend on your own vial's mg and how much bacteriostatic water you added — use the same concentration you mixed above.
What should I avoid combining — and what's synergistic?
Thymalin doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
Thymalin is available from BioLongevity Labs — use code OHM-15 at BioLongevity for 15% off. As always, buy only from a source that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity.
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
Thymalin is the prototype of the Khavinson short-peptide bioregulator family — a thymus-tissue polypeptide extract, not a single synthetic sequence — and it carries the deepest human evidence in that entire 13-member family. The evidence is real Russian cohort data spanning decades; it is also entirely non-RCT, single-research-group work that Western reviewers discount on methodology. Both things are true at once.
| Class | Polypeptide complex extracted from thymus tissue (not a single defined sequence) |
| Mechanism (one line) | Supports T-cell development and thymic function, aiming to restore immune competence lost as the thymus involutes with age |
| Evidence base | Deepest human record in the Khavinson family — 30 studies cited, 19 human — but zero RCTs; all Russian cohort work |
| Safety record | No serious adverse events documented in the Russian literature; mild/injection-site effects only |
| Regulatory status | research_only in the US, not FDA-approved; holds an actual clinical-use approval in Russia (alongside the related peptide Cortexin) |
What it is
Thymalin is the founding member of the Khavinson short-peptide bioregulator family — a body of research that began in 1970s Soviet military medicine at the Military Medical Academy in Leningrad, where researchers extracted tissue-specific peptide fractions from animal organs and observed bioactive effects when re-administered, especially in aged tissue. Vladimir Khavinson became the program’s central figure, and after 1991 the St. Petersburg Institute of Bioregulation and Gerontology became its institutional home.
Thymalin itself is the first-generation, extract-based product of that program: a polypeptide complex extracted from thymus tissue, not a synthesized single sequence like its “descendants” Thymagen and Vilon. Profiled by thepeptidelist.com under anti-aging (secondary use: immune), with an evidence tier of Moderate — 30 studies cited, 19 of them human. Thymalin is also one of the few Khavinson-family peptides with an actual clinical-use approval in Russia, alongside the related cortex peptide Cortexin.
How it works
Claimed mechanism: thymus-derived peptides supporting T-cell development and immune-system function — restoring immune competence in the aging (involuting) thymus, the organ where T-cells mature.
This sits inside the broader Khavinson-family theoretical claim: that short tissue-derived peptides can cross cell and nuclear membranes, bind DNA promoter regions, and modulate transcription in a tissue-specific way — with Thymalin’s extract acting as a “regulatory signal” for the thymus. In-vitro work across the family supports the underlying nuclear-penetration mechanism: short Khavinson peptides have been shown to penetrate HeLa-cell nuclei and interact with DNA (Fedoreyeva et al. 2011, Biochemistry (Mosc), 22117547), and to drive heterochromatin decondensation and gene reactivation in lymphocytes from elderly subjects (Khavinson, Lezhava, Malinin 2004, Bull Exp Biol Med, 15085253).
What the research shows
This is the deepest human record in the Khavinson family, though all of it is Russian cohort work with zero RCTs. Per KB doctrine, every third-party citation below carries until the citation-verification pass confirms it:
- Khavinson & Morozov 2003, Neuro Endocrinol Lett — 266 elderly patients, 6–8 yr follow-up; Thymalin + Epithalamin reported to reduce mortality 2.0–4.1 fold. 14523363.
- Khavinson & Morozov 2002, Adv Gerontol — same cohort, geroprotective effect. 12577695.
- Shustval’ 1992, Lik Sprava — 156 patients; normalized lipid metabolism and improved cardiac function in ischemic heart disease. 1481512.
- COVID-19 era: Thymalin added to standard therapy reported to accelerate decline in IL-6/CRP/D-dimer and reduce thrombosis risk (Khavinson, Kuznik et al. 2021, Stem Cell Rev Rep, 33575961), with a reported COVID-19 mortality of 20.6% in a Thymalin+Tocilizumab cohort (Kuznik et al. 2022, Adv Gerontol, 36169363).
- In-vitro: reductions in pro-inflammatory cytokines 1.4–6.0×; up to 6.8-fold increases in CD28 expression on T lymphocytes.
The honest read: a genuinely substantial human dataset by Russian-school standards — far deeper than anything else in the family — but no blinded RCT, and Western reviewers discount the cohort designs. Both statements are correct at the same time. The 0035 categorization pass graded Thymalin Tier C / Safety Green — PRIMARY longevity, SECONDARY immune — one of only three Khavinson-family members promoted to recommend-eligible.
Immune-group cross-link. The thymic-immune target here overlaps conceptually with Thymosin Alpha-1 — a separate, far better Western-evidenced thymic immune peptide (a 28-amino-acid thymosin fragment with real human trial data and active research-vendor availability). A reader wanting a thymus/immune peptide they can buy today from a verified-COA vendor is better served by Thymosin alpha-1; Thymalin and its Khavinson-family siblings Thymagen and Vilon are the deeper-history, Russian-school context around it.
Real-world protocol
Educational purposes only — this reflects what Russian-school protocols and the peptide community actually use, stated plainly; it is not medical advice.
There is no Western-validated dosing protocol for Thymalin. What exists is the Khavinson-school cycle pattern shared across the whole family (see the Khavinson bioregulator family and Epithalon for the same cycle logic):
- Cycle structure: a short course — typically 10–20 consecutive days — followed by a long rest, repeated 2–3 times per year. The framework claims effects persist 2–3 months past the end of a cycle (an “epigenetic-like persistence” rationale for cycling instead of continuous dosing) — asserted by the Khavinson program, not independently confirmed.
- Thymalin specifically: historically given as a small intramuscular injection over a short in-clinic course in Russian protocols exact mg — because it’s a tissue extract rather than a single synthetic sequence, its dosing convention differs from the synthetic short peptides in the family (which run ~100–200 mcg/day).
- Storage: lyophilized powder is stable cold; once reconstituted with bacteriostatic water, refrigerate and use within roughly 28 days.
Because per-peptide human dose-finding data doesn’t exist for this family, treat every number above as community/Russian-protocol convergence, not a validated dose.
Side effects & management
The reported adverse-event profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle. No serious AEs documented at standard doses.
The real risk with Thymalin isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space. Most buyers are sourcing a Russian-school peptide from a forum link with no way to verify identity or purity, and counterfeit/mislabeled product is the most common failure mode for exactly these compounds — Thymalin included, and arguably more so given it’s a tissue-extract mixture rather than a single synthesizable sequence, which makes it harder to verify by casual means. Third-party COA verification matters more here than for almost any other peptide class.
Regulatory status
Thymalin is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance. Notably, Thymalin and the related cortex peptide Cortexin hold clinical-use approvals in Russia — that approval does not extend to the US.
Sources
- primary profile (thepeptidelist.com directory capture, 2026-06-07).
- 0035 tier/safety/goal grading: Thymalin promoted to C-green.
- Thymalin human-cohort/clinical PMIDs: 14523363, 12577695, 1481512, 33575961, 36169363 — all pending citation-verification pass.
- Family-mechanism PMIDs: 22117547 (Fedoreyeva et al. 2011, nuclear penetration), 15085253 (Khavinson/Lezhava/Malinin 2004, chromatin decondensation).
- Related: Thymagen · Vilon · Thymosin Alpha-1 · Epithalon · the Khavinson bioregulator family.
Sources & references
- primary profile (thepeptidelist.com directory capture, 2026-06-07).
- 0035 tier/safety/goal grading: Thymalin promoted to C-green.
- Thymalin human-cohort/clinical PMIDs: 14523363, 12577695, 1481512, 33575961, 36169363 — all pending citation-verification pass.
- Family-mechanism PMIDs: 22117547 (Fedoreyeva et al. 2011, nuclear penetration), 15085253 (Khavinson/Lezhava/Malinin 2004, chromatin decondensation).
- Related: Thymagen · Vilon · Thymosin Alpha-1 · Epithalon · the Khavinson bioregulator family.